<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="31e3d3a6-c592-499f-e063-6394a90a58d3"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>CLEMASZ ™
 <br/>
(Clemastine Fumarate Tablets, USP)
 <br/>
Rx only
</title>
   <effectiveTime value="20250403"/>
   <setId root="861f5615-297e-44af-a7eb-1095dc29d0a0"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="119177168"/>
            <name>New HeightsRx, LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3395c120-9a63-a900-e063-6394a90ae277"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250403"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="84044-268" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>CLEMASZ</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Clemastine Fumarate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="J2B2A4N98G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE, UNSPECIFIED FORM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.68"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="19259EGQ3D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CLEMASTINE FUMARATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="95QN29S1ID" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CLEMASTINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="84044-268-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250401"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA073283" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250401"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">NH;268</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-2335-3ab3-e063-6294a90a7b63"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250403"/>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-2336-3ab3-e063-6294a90a7b63"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Clemastine belongs to the benzhydryl ether group of antihistaminic compounds. The chemical name is (+)-(2
 
  <content styleCode="italics">R</content>)-2-[2-[[(
 
  <content styleCode="italics">R</content>)-
 
  <content styleCode="italics">p</content>-Chloro-α-methyl-α-phenylbenzyl]-oxy]ethyl]-1-methylpyrrolidine fumarate (1:1).

 </paragraph>
                  <table width="100%">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="right" valign="top"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="center">
                              <renderMultiMedia referencedObject="MM1"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left">C
    
     <sub>21</sub>H
    
     <sub>26</sub>C1NO∙C
    
     <sub>4</sub>H
    
     <sub>4</sub>O
    
     <sub>4</sub>
                           </td>
                           <td align="right">M.W. 459.97</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Each tablet for oral administration contains 2.68 mg of clemastine fumarate, USP.</paragraph>
                  <paragraph>Inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, povidone, pregelatinized starch and stearic acid.</paragraph>
               </text>
               <effectiveTime value="20250403"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="clemastine-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-2337-3ab3-e063-6294a90a7b63"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Clemastine fumarate is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells. The inherently long duration of antihistaminic effects of clemastine fumarate has been demonstrated in wheal and flare studies. In normal human subjects who received histamine injections over a 24-hour period, the antihistaminic activity of clemastine reached a peak at 5 to 7 hours, persisted for 10 to 12 hours and, in some cases, for as long as 24 hours. Pharmacokinetic studies in man utilizing
 
  <sup>3</sup>H and
 
  <sup>14</sup>C labeled compound demonstrates that: clemastine is rapidly and nearly completely absorbed from the gastrointestinal tract, peak plasma concentrations are attained in 2 to 4 hours, and urinary excretion is the major mode of elimination.

 </paragraph>
               </text>
               <effectiveTime value="20250203"/>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-2338-3ab3-e063-6294a90a7b63"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>CLEMASZ ™ (Clemastine Fumarate Tablets USP) 2.68 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. CLEMASZ ™ (Clemastine Fumarate Tablets USP) 2.68 mg are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. It should be noted that clemastine fumarate is indicated for the dermatologic indications at the 2.68 mg dosage level only.</paragraph>
               </text>
               <effectiveTime value="20250403"/>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-2339-3ab3-e063-6294a90a7b63"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <effectiveTime value="20250203"/>
               <component>
                  <section>
                     <id root="31e3bf7e-233a-3ab3-e063-6294a90a7b63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Usage in Nursing Mothers</title>
                     <text>
                        <paragraph>Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.</paragraph>
                     </text>
                     <effectiveTime value="20250203"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="31e3bf7e-233b-3ab3-e063-6294a90a7b63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Usage in Lower Respiratory Disease</title>
                     <text>
                        <paragraph>Antihistamines
 
  <content styleCode="italics">should</content>not be used to treat lower respiratory tract symptoms including asthma. Antihistamines are also contraindicated in the following conditions:

 </paragraph>
                        <paragraph>Hypersensitivity to clemastine fumarate or other antihistamines of similar chemical structure.</paragraph>
                        <paragraph>Monoamine oxidase inhibitor therapy (see
 
  <linkHtml href="#DI">Drug Interactions</linkHtml>section).

 </paragraph>
                     </text>
                     <effectiveTime value="20250203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-233c-3ab3-e063-6294a90a7b63"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Antihistamines should be used with considerable caution in patients with: narrow angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, and bladder neck obstruction.</paragraph>
               </text>
               <effectiveTime value="20250203"/>
               <component>
                  <section>
                     <id root="31e3bf7e-233d-3ab3-e063-6294a90a7b63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Usage in Children</title>
                     <text>
                        <paragraph>Safety and efficacy of clemastine fumarate have not been established in children under the age of 12 years.</paragraph>
                     </text>
                     <effectiveTime value="20250203"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="31e3bf7e-233e-3ab3-e063-6294a90a7b63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Usage in Pregnancy</title>
                     <text>
                        <paragraph>Experience with this drug in pregnant women is inadequate to determine whether there is exists a potential for harm to the developing fetus.</paragraph>
                     </text>
                     <effectiveTime value="20250203"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="31e3bf7e-233f-3ab3-e063-6294a90a7b63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Usage with CNS Depressants</title>
                     <text>
                        <paragraph>Clemastine has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.).</paragraph>
                     </text>
                     <effectiveTime value="20250203"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="31e3bf7e-2340-3ab3-e063-6294a90a7b63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Usage in Activities Requiring Mental Alertness</title>
                     <text>
                        <paragraph>Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.</paragraph>
                     </text>
                     <effectiveTime value="20250203"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="31e3bf7e-2341-3ab3-e063-6294a90a7b63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Usage in the Elderly (approximately 60 years or older)</title>
                     <text>
                        <paragraph>Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.</paragraph>
                     </text>
                     <effectiveTime value="20250203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-2342-3ab3-e063-6294a90a7b63"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <paragraph>Clemastine fumarate should be used with caution in patients with: history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, and hypotension.</paragraph>
               </text>
               <effectiveTime value="20250203"/>
               <component>
                  <section ID="DI">
                     <id root="31e3bf7e-2343-3ab3-e063-6294a90a7b63"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.</paragraph>
                     </text>
                     <effectiveTime value="20250203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-2344-3ab3-e063-6294a90a7b63"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Transient drowsiness, the most common adverse reaction associated with clemastine fumarate, occurs relatively frequently and may require discontinuation of therapy in some instances.</paragraph>
               </text>
               <effectiveTime value="20250203"/>
               <component>
                  <section>
                     <id root="31e3bf7e-2345-3ab3-e063-6294a90a7b63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Antihistaminic Compounds</title>
                     <text>
                        <paragraph>It should be noted that the following reactions have occurred with one or more antihistamines and, therefore, should be kept in mind when prescribing drugs belonging to this class, including clemastine. The most frequent adverse reactions are italicized.</paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>
                              <content styleCode="bold">General:</content>Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of the mouth, nose, and throat.
 
  </item>
                           <item>
                              <content styleCode="bold">Cardiovascular System:</content>Hypotension, headache, palpitations, tachycardia, extrasystoles.
 
  </item>
                           <item>
                              <content styleCode="bold">Hematologic System:</content>Hemolytic anemia, thrombocytopenia, agranulocytosis.
 
  </item>
                           <item>
                              <content styleCode="bold">Nervous System:</content>
                              <content styleCode="italics">Sedation, sleepiness, dizziness, disturbed coordination</content>, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesias, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.
 
  </item>
                           <item>
                              <content styleCode="bold">GI System:</content>Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.
 
  </item>
                           <item>
                              <content styleCode="bold">GU System:</content>Urinary frequency, difficult urination, urinary retention, early menses.
 
  </item>
                           <item>
                              <content styleCode="bold">Respiratory System:</content>Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.
 
  </item>
                        </list>
                     </text>
                     <effectiveTime value="20250203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-2346-3ab3-e063-6294a90a7b63"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Antihistamine overdosage reactions may vary from central nervous system depression to stimulation.</paragraph>
                  <paragraph>Stimulation is particularly likely in children. Atropine-like signs and symptoms: dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.</paragraph>
                  <paragraph>
                     <content styleCode="italics">If vomiting has not occurred spontaneously</content>the conscious patient should be induced to vomit. This is best done by having him drink a glass of water or milk after which he should be made to gag. Precautions against aspiration must be taken, especially in infants and children. If vomiting is unsuccessful gastric lavage is indicated within 3 hours after ingestion and even later if large amounts of milk or cream were given beforehand. Isotonic and 1/2 isotonic saline is the lavage solution of choice.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Saline cathartics</content>, such as milk of magnesia, by osmosis draw water into the bowel and therefore, are valuable for their action in rapid dilution of bowel content.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Stimulants</content>should
 
  <content styleCode="italics">not</content>be used.

 </paragraph>
                  <paragraph>Vasopressors may be used to treat hypotension.</paragraph>
               </text>
               <effectiveTime value="20250203"/>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-2347-3ab3-e063-6294a90a7b63"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND RESPONSE OF THE PATIENT.</paragraph>
               </text>
               <effectiveTime value="20250403"/>
               <component>
                  <section>
                     <id root="31e3bf7e-2348-3ab3-e063-6294a90a7b63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>CLEMASZ ™ (Clemastine Fumarate Tablets, USP) 2.68 mg</title>
                     <text>
                        <paragraph>The maximum recommended dosage is one tablet three times daily. Many patients respond favorably to a single dose which may be repeated as required, but not to exceed three tablets daily.</paragraph>
                     </text>
                     <effectiveTime value="20250403"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-2349-3ab3-e063-6294a90a7b63"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>CLEMASZ ™ (Clemastine Fumarate Tablets, USP) 2.68 mg are white, round, scored tablets debossed with "NH" and "268". Tablets are packaged in bottles of 30 (NDC 84044-268-03).</paragraph>
               </text>
               <effectiveTime value="20250403"/>
               <component>
                  <section>
                     <id root="31e3bf7e-234a-3ab3-e063-6294a90a7b63"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 20° to 25°C (68° to 77°F)</paragraph>
                        <paragraph>[See USP Controlled Room Temperature].</paragraph>
                        <paragraph>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</paragraph>
                     </text>
                     <effectiveTime value="20250403"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-234b-3ab3-e063-6294a90a7b63"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured For: 
  <br/>  New HeightsRx, LLC 
  <br/>  1225 Ave. Ponce de Leon
 
  <content styleCode="bold">PH - 1562</content>
                     <br/>  San Juan, Puerto Rico 00907

 </paragraph>
                  <paragraph>Rev. 04/2025</paragraph>
               </text>
               <effectiveTime value="20250403"/>
            </section>
         </component>
         <component>
            <section>
               <id root="31e3bf7e-234c-3ab3-e063-6294a90a7b63"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2.68 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 84044-268-03</paragraph>
                  <paragraph>Clemastine 
  <br/>  Fumarate 
  <br/>  Tablets, USP
 </paragraph>
                  <paragraph>2.68 mg</paragraph>
                  <paragraph>Rx only 
  <br/>  100 Tablets
 </paragraph>
                  <paragraph>New HeightsRx, LLC.</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250403"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 2.68 mg Tablet Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="CLEMASZ-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>